title: Early failure of coronary artery bypass grafts: an albumin cross-linked glutaraldehyde (BioGlue) related complication.
abstract: Bioglue which constitutes albumin cross linked with glutaraldehyde (ACLG) produced by Cryolife, Inc, Kennesaw, GA was introduced as a better alternative to GRF glue with less tissue necrosis. We report a case of a 69-year-old male who developed stenosis of his saphenous vein and internal thoracic artery bypass grafts, requiring re-do coronary artery bypass grafting. Both fibrotic narrowing were in close proximity to the site of Bioglue application and appears to be a reaction to the glue. The advent of ACLG has facilitated surgery; however, this case highlights a potential side effect, emphasizing the judicious use of this hemostatic agent in patients.
authors.affiliation: Department of Cardiothoracic Surgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. hkhan76@hotmail.com
authors.forename: Habib
authors.initials: H
authors.lastname: Khan
authors.forename: Sanjay
authors.initials: S
authors.lastname: Chaubey
authors.forename: Jatin
authors.initials: J
authors.lastname: Desai
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D023903:Coronary Restenosis / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D023921:Coronary Stenosis / Q000175:diagnosis / Q000601:surgery; D004452:Echocardiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011506:Proteins / Q000009:adverse effects*; D012086:Reoperation / Q000379:methods; D013997:Time Factors; D017211:Treatment Failure
chemical_list: C472676:Bio-glue; D011506:Proteins